The most definitive classification systems for dementia are based on the underlying
pathology which, in turn, is categorized largely according to the observed accumulation of …

The greatest unmet therapeutic need in Parkinson's disease is the development of treatment
that slows the relentless progression of the neurodegenerative process. The concept of …

The genetic basis of Lewy body dementia (LBD) is not well understood. Here, we performed
whole-genome sequencing in large cohorts of LBD cases and neurologically healthy …

Parkinson's disease (PD) is the second most common degenerative disorder. Although the
disease was described more than 200 years ago, its pathogenetic mechanisms have not yet …

Dementia with Lewy bodies (DLB) is an age-associated neurodegenerative disorder
producing progressive cognitive decline that interferes with normal life and daily activities …

Parkinson's disease is a common, progressive neurodegenerative disorder, affecting 3% of
those older than 75 years of age. Clinically, Parkinson's disease (PD) is associated with …

Dementia is increasingly being recognized in cases of Parkinson's disease (PD); such cases
are termed PD dementia (PDD). The spread of fibrillar α-synuclein (α-syn) pathology from …

Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …

Heterozygous mutations in the glucocerebrosidase gene (GBA) represent the strongest
common genetic risk factor for Parkinson's disease (PD), the second most common …

Mutations in the acid β-glucocerebrosidase (GBA1) gene, responsible for the lysosomal
storage disorder Gaucher's disease (GD), are the strongest genetic risk factor for Parkinson's …